Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007499 | 0.92 | KEAP1 (0.44) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL10625992 | 0.84 | TSHR (0.44) | SMN1; SMN2ALDH1A1TSHRPOLBAPEX1 | |
| SCHEMBL10628886 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1TP53TSHRCASP1 | |
| SCHEMBL32668944 | 0.83 | KEAP1 (0.55) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL3436916 | 0.83 | KDM4E (0.45) | KEAP1NFE2L2ALDH1A1LMNANOTUM | |
| SCHEMBL979056 | 0.83 | KEAP1 (0.55) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL221449 | 0.81 | KEAP1 (0.53) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL365017 | 0.81 | KDM4E (0.44) | KEAP1NFE2L2ALDH1A1NOTUMHPGD | |
| Hydrochloric Acid SCHEMBL9488278 | 0.81 | KEAP1 (0.53) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL19399612 | 0.81 | KEAP1 (0.44) | KEAP1NFE2L2ALDH1A1TSHRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150297566-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2015-10-22 | — | — | US | disclosed |
| US-9095583-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2379174-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| CN-101842361-A | Pyrazinone derivatives and their use in the treatment of lung diseases | ASTRAZENECA AB | 2010-09-22 | — | — | CN | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-4762844-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0181588-A2 | Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids, process for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | KEAP1 190/4885NFE2L2 314/4885SMN1; SMN2 3152/4885 |
| US-20150297566-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | KEAP1 2775/4885NFE2L2 3092/4885SMN1; SMN2 3233/4885 |
| US-20170340610-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | KEAP1 2633/4885NFE2L2 2783/4885SMN1; SMN2 3364/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | KEAP1 865/4885NFE2L2 1934/4885SMN1; SMN2 4309/4885 |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | KEAP1 3412/4885NFE2L2 3238/4885SMN1; SMN2 3537/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | KEAP1 156/4885NFE2L2 331/4885SMN1; SMN2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.